- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals productsBusiness Overview: Company is a subsidiary of Fredun Group. It manufactures pharmaceutical and allopathic formulations viz. tablets, syrups, capsules, and ointments. Product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral and anti-hypertensive. Company also ventured into manufacturing of dietary/herbal supplements,...
Fredun Pharmaceuticals has launched PAWTALKS, a new digital platform for discussions on pet and animal healthcare. This initiative aims to bring together veterinary experts, pet parents, and industry leaders to share knowledge and foster informed conversations. PAWTALKS, available on YouTube and Instagram, will cover essential topics like preventive healthcare, nutrition,...
Fredun Pharmaceuticals Limited's Equity Shares are now officially available for trading on the National Stock Exchange of India Limited (NSE). Already listed on BSE, the company's shares can now be traded on India's other primary exchange under the symbol FREDUN. This move significantly broadens market access for the stock. For...
Fredun Pharmaceuticals discussed its strong Q1 results, reporting a 90% revenue growth to INR228.25 Cr, EBITDA up 93% to INR32.78 Cr, and net profit up 95% to INR13.17 Cr. The company expects 30-35% blended annual growth for its diverse portfolio, driven by new age brands and capacity expansion. Its Fredun...
Fredun Pharmaceuticals Limited has announced an earnings conference call for Q1 FY27 on Thursday, 13th August, 2026, at 11:30 a.m. The call will feature Managing Director Mr. Fredun Medhora and aims to discuss the company's performance for the first quarter of the fiscal year. This event offers a crucial opportunity...
Fredun Pharmaceuticals has released its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported a total income from operations of 482.43 Cr. Net profit for the quarter stood at 36.03 Cr, with Earnings Per Share (EPS) reaching 83.3. These results, approved by the Board, offer...